Anixa Biosciences (NASDAQ: ANIX) — Perfil da empresa, notícias e dados financeiros
Anixa Biosciences develops immune system-based cancer treatments, including a breast cancer vaccine and CER-T technology for prostate cancer.
Anixa Biosciences
Anixa Biosciences (NASDAQ:ANIX) is a biotechnology firm focused on harnessing the body's immune system to fight cancer. Dedicated to developing a range of innovative treatments and vaccines, Anixa's operations span from early research to clinical trials. The company is especially known for its work in developing a cancer vaccine technology aimed at preventing breast cancer, as well as chimeric endocrine receptor T-cell (CER-T) technology targeting prostate cancer. With a commitment to advancing healthcare, Anixa's objectives include bringing groundbreaking immunotherapies and vaccines to market, offering new hope in the fight against cancer.
Resumo
Operações
Produtos e/ou serviços de Anixa Biosciences
- Breast cancer vaccine development focused on preventing the recurrence and development of triple-negative breast cancer, utilizing immunotherapy approaches.
- Ovarian cancer vaccine, leveraging the same technology platform as the breast cancer vaccine for prevention and inhibitory growth of ovarian tumors.
- CAR-T technology for solid tumors, innovating cellular therapy to target and destroy cancer cells in various solid tumor types.
- Cchek™, a proprietary AI-based platform for early cancer detection, using machine learning to analyze simple blood tests for multiple cancer types.
- Prostate cancer therapy, focusing on a novel approach to treat early-stage prostate cancer non-invasively, aiming to reduce side effects associated with current treatments.
- Collaboration with Cleveland Clinic on developing vaccines, reflecting a strategic partnership to advance prevention therapies for various cancers.
equipe executiva do Anixa Biosciences
- Amit KumarCEO, Chairman & Co-Chair of CBAB
- Michael J. CatelaniPresident, COO, CFO & Corporate Secretary
- Pamela D. GarzoneChief Development Officer & Chair Breast Cancer Clinical Advisory Board
Últimas notícias sobre a Anixa Biosciences
Principais indicadores financeiros
Resultados divulgados pela Anixa Biosciences, em USD.
- Cap. de mercado
- 117,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -11,7 mi | -10,9 mi | |
| 0 | -13,8 mi | -12,6 mi | |
| 210 mil | -11 mi | -9,8 mi | |
| 2,5 bi | -13,9 mi | -13,6 mi |